About
15% of all breast cancer patients are diagnosed with triple-negative breast cancer. Triple-negative breast cancer
got its name because the cells test negative for estrogen receptors,
progesterone receptors, and HER2 receptors.
Since triple-negative breast cancer lacks these receptors, it cannot be
targeted by any drugs that are available for the treatment of other types of
breast cancer. Triple-negative breast
cancer patients typically have shorter survival rates than patients who are
affected by other forms of breast cancer.
Previous studies have shown that breast stem cells
are an integral part of breast growth and development during puberty and
pregnancy. This study has demonstrated that
ID4 is responsible for whether or not the breast stem cells develop into
specialist cells. The researchers were
able to demonstrate that blocking ID4 in a breast stem cell activates genes that
drive cell specialization, estrogen receptors, and other genes that are
expressed by forms of breast cancer that are less aggressive. The researchers are hopeful that by blocking
ID4 in the aggressive form of triple-negative breast cancer, they will be able
to treat it with tamoxifen. Tamoxifen is
the drug that is used to treat estrogen receptor-positive breast cancers.
I found the results of this study
remarkable. I think the findings of this
study will provide a lot of hope for those who are diagnosed with triple
negative breast cancer. Hopefully future
studies involving the investigation of ID4 will provide further understanding
of how to treat triple-negative breast cancers.
Thank you very Steady info ... hopefully more successful.
ReplyDeleteObat Herbal Tumor Jinak Pada Payudara